Interferon beta-1b is effective and has a favourable safety profile in Chinese patients with relapsing forms of multiple sclerosis

ZX Li; CZ Lu; XH Zhang; LY Cui; XH Xu; Radue, E.; SG Chu; LR Wang; Beckmann, K.; Lampe, J.; Pohl, C.; Stemper, B.; Sandbrink, R.
June 2014
Neurology Asia;Jun2014, Vol. 19 Issue 2, p179
Academic Journal
Background & Objective: No clinical study of any interferon beta therapy has yet been successfully conducted in Chinese multiple sclerosis patients, probably due to the low incidence of this disease in China. The primary objective of this study was to demonstrate that treating multiple sclerosis patients of Chinese origin with interferon beta-1b has a beneficial effect on disease course, as measured by the decrease of newly active lesions on magnetic resonance imaging. Methods: Chinese patients diagnosed with relapsing-remitting or secondary-progressive multiple sclerosis were enrolled in this multicenter, open label, single-arm study. Following a 3-month pre-treatment phase, patients were treated with 250 μg interferon beta-1b subcutaneously every other day for 6 months. Patients had regular assessments for treatment safety and efficacy of the treatment. Results: Thirty seven patients completed the trial. Significant decreases in the number of newly active lesions were observed in the 6-month treatment period compared with the pre-treatment period (median decrease 1.5 lesions, p<0.001). Most adverse events were mild and transient and no serious ones were observed. Conclusions: Treatment with interferon beta-1b significantly reduced the occurrence of new lesions and was well tolerated in this Chinese population. These findings support the use of interferon beta- 1b for treating Chinese MS patients.


Related Articles

  • BENEFIT 8-year results provide further support for the long-term value of early treatment of multiple sclerosis. Fujihara, K. // Journal of Neurology, Neurosurgery & Psychiatry;Nov2014, Vol. 85 Issue 11, p1179 

    The article looks at a study which shows 8-year results of interferon beta 1b therapy in patients of clinically isolated syndrome (CIS), a first event of multiple sclerosis (MS). It mentions the placebo-controlled study to determine the effect of interferon beta 1b therapy in patients and...

  • From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. Prosperini, Luca; Mancinelli, Chiara Rosa; Pozzilli, Carlo; Grasso, Maria Grazia; Clemenzi, alessandro; Collorone, Sara; Pontecorvo, Simona; Francia, ada; Villani, Veronica; Koudriavtseva, Tatiana; Buttari, Fabio; Centonze, Diego; Di Battista, Giancarlo; Frisullo, Giovanni; Galgani, Simonetta; Gasperini, Claudio // European Neurology;May2014, Vol. 71 Issue 5/6, p233 

    Objectives: To investigate whether clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) who required a reduction of administration frequency of interferon-beta (IFNB) were similar to those of patients who did not. Methods: We identified three subgroups...

  • Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Hartung, Hans-Peter; Kappos, Ludwig; Goodin, Douglas; O'Connor, Paul; Filippi, Massimo; Arnason, Barry; Comi, Giancarlo; Cook, Stuart; Jeffery, Douglas; Petkau, John; White, Richard; Bogumil, Timon; Beckmann, Karola; Stemper, Brigitte; Suarez, Gustavo; Sandbrink, Rupert; Pohl, Christoph // Journal of Neurology;Nov2015, Vol. 262 Issue 11, p2466 

    Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disease of the CNS that requires long-term treatment. The identification of patient characteristics that can help predict disease outcomes could improve care for patients with MS. The objective of this study is to identify...

  • Don't Delay Optic Neuritis Dx. Sowka, Joseph W.; Kabat, Alan G. // Review of Optometry;12/15/2015, Vol. 152 Issue 12, p74 

    The article discusses about the Optic neuritis is an inflammation of the optic nerve that often occurs in association with multiple sclerosis (MS) and the use of Magnetic resonance imaging (MRI) is highly sensitive for and specific in the assessment of inflammatory changes in the optic nerves....

  • MS TREATMENT OPTIMIZATION: FACTORS ASSOCIATED WITH POOR CLINICAL RESPONSE IN NAB POSITIVE PATIENTS. Cornea, A.; Tudor, R.; Petre, A.; Simu, M. // Romanian Journal of Neurology;2016, Vol. 15 Issue 3, p119 

    Background and purpose. Interferon beta (IFN beta) belongs to the fi rst line of disease modifying therapy drugs in the treatment of relapsing-remitting multiple sclerosis being widely used in the chronic treatment of this pathology. The serum presence of the neutralizing antibodies (Nabs) has...

  • Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade. Ribes García, Sara; Gómez-Pajares, Fernando; albelda Puig, Carmen; García Herrera, José Luis; Casanova Estruch, Bonaventura // European Neurology;Jul2016, Vol. 75 Issue 5/6, p274 

    Background: More than 3,000 multiple sclerosis (MS) patients were treated with disease-modifying drugs (DMDs) in the Region of Valencia during 2005-2014. We aimed at describing the demographic and clinical characteristics of MS patients who requested treatment with DMDs, variations in their use,...

  • Multiple Sclerosis With Initial Stroke-Like Clinicoradiologic Features: Case Report and Literature Review. Przeklasa-Auth, Melissa; Ovbiagele, Bruce; Yim, Catherine; Shewmon, D. Alan // Journal of Child Neurology;Jun2010, Vol. 25 Issue 6, p732 

    A 17-year-old male presented with sudden onset of persistent focal neurological symptoms. Magnetic resonance imaging (MRI) demonstrated a nonenhancing white matter lesion that appeared hyperintense on fluid-attenuated inversion recovery sequence and diffusion-weighted imaging, while hypointense...

  • An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart injection device. Willis, Helen; Webster, Julie; Larkin, Anne Marie; Parkes, Laura // Patient Preference & Adherence;2014, Vol. 8, p843 

    Background: Poor adherence to disease-modifying drugs is associated with an increased risk of relapse in patients with multiple sclerosis. However, adherence is difficult to assess objectively. RebiSmart® (Merck Serono SA, Geneva, Switzerland), a device for subcutaneous (sc) injection of...

  • Preparation of monoPEGylated human interferon beta-1a: Optimization of the conditions for N-terminal PEGylation. Korzhavin, D.; Chernovskaya, T.; Efanov, Yu.; Rudenko, E.; Ivanov, R.; Pshenichnikova, A.; Shvets, V. // Applied Biochemistry & Microbiology;Dec2015, Vol. 51 Issue 7, p774 

    The recombinant human interferon (IFN) beta-1a was modified with polyethylene glycol (PEG). The reaction was performed with the use of activated linear butyraldehyde PEG derivative with a molecular weight of 30 kDa. As a result of the multifactorial experiment, the correlation between the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics